Dulaglutide
GLP-1 receptor agonist sold as Trulicity. Once-weekly injectable approved for type 2 diabetes and cardiovascular risk reduction with a long-acting FC fusion protein format.
0 anonymous reports
Also known as:
trulicityly2189265
browse topics:
community guides:
No reports found.
Community Q&A
- How does dulaglutide compare to semaglutide for weight loss?
- Community accounts consistently describe semaglutide as producing greater weight loss than dulaglutide at equivalent effort and cost. Dulaglutide accounts appear predominantly from people prescribed it for type 2 diabetes before semaglutide's wider availability, or for cardiovascular risk reduction. Weight loss in confessions is described as moderate — meaningful but not the dramatic losses reported on semaglutide or tirzepatide.
- What are the side effects of Trulicity?
- Community accounts describe a GI side effect profile similar to other GLP-1 agents: nausea, reduced appetite, and occasional vomiting, most pronounced in the first 4–8 weeks. Compared to semaglutide, accounts describe dulaglutide's side effects as similar or slightly milder. Injection site reactions and belching appear more frequently in dulaglutide accounts than in semaglutide accounts — attributed to differences in formulation.